As a new filing with the Securities and Exchange Commission showed, billionaire Steve Cohen‘s Point72 Asset Management has initiated a stake in Celator Pharmaceuticals Inc (NASDAQ:CPXX) amid a 500% jump registered by the stock. The 13G filing showed that Point72 currently owns almost 2.26 million shares of Celator, which represent 6.5% of the company’s outstanding stock.
Celator’s stock surged after the company announced positive results from the Phase 3 trial of its drug candidate in patients with blood cancer. Overall, the median survival for patients treated with Celator’s VYXEOS was 9.56 months, versus 5.96 months for patients treated with standard care regimen, known as 7+3. Celator plans to submit submit its New Drug Application later this year.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|EverPoint Asset Management||0||600,000||0||600,000||600,000||1.7%|
|Steven A. Cohen||0||2,855,000||0||2,855,000||2,855,000||8.3%|
Page 1 of 9 SEC Filing
(Amendment No. )*
CELATOR PHARMACEUTICALS, INC.
Common Stock, Par Value $0.001 Per Share